ebook Munafa Stock Market Course + Intraday & FNO calls  

       

GLENMARK NEWS why is Glenmark Pharmaceuticals Limited price falling or rising

GLENMARK NEWS reasons for why stock price of Glenmark Pharmaceuticals Limited is falling or rising

GLENMARK Glenmark Pharmaceuticals is falling or rising technical reasons

Technical analysis forecast of Glenmark Pharmaceuticals Stock is that its in a uptrend for shortterm, and I will avoid taking a SHORT or SELL trade in this stock. Look for opportunities to BUY or go LONG in Glenmark Pharmaceuticals GLENMARK at this time. Stock is rising and might rise more.

It appears as if Glenmark Pharmaceuticals GLENMARK gave a large move recently.

Stock of Glenmark Pharmaceuticals (GLENMARK) is trading above an important moving average line, but it crossed this line recently, which means that it could show a small or a large fall soon enough depending on its trend.

My analysis of Glenmark Pharmaceuticals is bullish for shortterm, but stock is in semi over bought zones and there are some chances of seeing a fall tomorrow. Use 2185.5 as stoploss in an intra day sell trade for a target of 2135.37. However, stock will show a bullish move above 2185.5.

GLENMARK Glenmark Pharmaceuticals is falling or rising NEWS fundamental reasons

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 09, 2026, titled "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg". - NEWS as on 2026-04-09

Company Announcement Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. - NEWS as on 2026-04-06

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expand - NEWS as on 2026-04-02

Company Announcement Glenmark Pharmaceuticals Launches GLIPIQⓇ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325. - NEWS as on 2026-03-23

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch - NEWS as on 2026-03-16

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Compet - NEWS as on 2026-03-04

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, - NEWS as on 2026-02-27

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about ESG Rating. - NEWS as on 2026-02-23

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - NEWS as on 2026-02-18

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about Transcript - NEWS as on 2026-02-04

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet - NEWS as on 2026-02-03

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about Link of Recording - NEWS as on 2026-02-02

Company Announcement Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation - NEWS as on 2026-02-01

More announcements and NEWS

GLENMARK Glenmark Pharmaceuticals Limited current price & indicator signals

Moving Averages for Glenmark Pharmaceuticals Limited

  • 5Day Average: 2144.94
  • 12Day Average: 2131.08
  • 20Day Average: 2152.9
  • 50Day Average: 2081.07
  • 100Day Average: 2026.43
  • 150Day Average: 2000.08
  • 200Day Average: 1995.14

GLENMARK Indicators & signals

Indicator MACD (12,26,9)

2141.81, 2128.22, 15.35
Indicator MACD is in positive zone

Indicator ADX (14)

10.9, 24.37, 19.58
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 52
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of GLENMARK Glenmark Pharmaceuticals Limited are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
10 Fri Apr 2026 2163.20 2148.90 to 2198.90 -0.27% 0.95 times
09 Thu Apr 2026 2169.10 2142.00 to 2186.20 -0.2% 0.87 times
08 Wed Apr 2026 2173.50 2129.60 to 2187.00 2.81% 0.77 times
07 Tue Apr 2026 2114.10 2068.20 to 2138.00 0.44% 0.55 times
06 Mon Apr 2026 2104.80 2036.70 to 2112.80 0.62% 0.83 times
02 Thu Apr 2026 2091.80 1966.50 to 2098.40 -0.44% 1.38 times
01 Wed Apr 2026 2101.10 2085.00 to 2238.40 -1.44% 1.44 times
30 Mon Mar 2026 2131.70 2108.70 to 2170.80 -1.79% 1.7 times
27 Fri Mar 2026 2170.50 2146.60 to 2188.40 0.09% 1.06 times
25 Wed Mar 2026 2168.50 2102.40 to 2179.70 3.47% 0.63 times
24 Tue Mar 2026 2095.70 2078.30 to 2137.10 0.32% 0.77 times
23 Mon Mar 2026 2089.00 2079.90 to 2170.00 -4.18% 0.58 times

Videos related to: GLENMARK NEWS why is Glenmark Pharmaceuticals Limited price falling or rising

Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You

Hindi Basics How To Trade In FnO Futures Options Stock Market

GLENMARK NEWS why is Glenmark Pharmaceuticals Limited price falling or rising

 

Back to top